Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
Status:
Completed
Trial end date:
2017-04-07
Target enrollment:
Participant gender:
Summary
Determine the safety, tolerability, dose-limiting toxicities (DLTs), maximum tolerated dose
(MTD), and recommended Phase 2 dose (RP2D) of ACY-241 in combination with ipilimumab and
nivolumab in patients with unresectable Stage III/Stage IV melanoma.
Phase:
Phase 1
Details
Lead Sponsor:
Acetylon Pharmaceuticals Incorporated Celgene
Collaborators:
ApoCell, Inc. Celerion INC Research New York University School of Medicine NYU Langone Health Syneos Health